Literature DB >> 18006819

The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.

Masaki Kunizaki1, Ryuji Hamamoto, Fabio Pittella Silva, Kiyoshi Yamaguchi, Takeshi Nagayasu, Masabumi Shibuya, Yusuke Nakamura, Yoichi Furukawa.   

Abstract

We previously identified SMYD3 as a histone methyltransferase and showed that its expression was elevated in colorectal, hepatocellular, and breast carcinomas. In the investigation of methyltransferase activity of SMYD3, we have found that vascular endothelial growth factor receptor 1 (VEGFR1) was also methylated by SMYD3. We further identified the methylated residue at VEGFR1 lysine 831, which is located in the kinase domain and is conserved among VEGFR1 orthologues. We also found that the lysine is followed by serine, which is conserved among some of the methylation targets of histone methyltransferases. Furthermore, methylation of VEGFR1 enhanced its kinase activity in cells. These data should be helpful for the profound understanding of the biological role of SMYD3 and regulatory mechanisms of VEGFR1. Additionally our finding may facilitate the development of strategies that may inhibit the progression of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006819     DOI: 10.1158/0008-5472.CAN-07-1132

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

1.  Crystal structure of cardiac-specific histone methyltransferase SmyD1 reveals unusual active site architecture.

Authors:  Nualpun Sirinupong; Joseph Brunzelle; Jun Ye; Ali Pirzada; Lindsey Nico; Zhe Yang
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

Review 2.  SET for life: biochemical activities and biological functions of SET domain-containing proteins.

Authors:  Hans-Martin Herz; Alexander Garruss; Ali Shilatifard
Journal:  Trends Biochem Sci       Date:  2013-10-20       Impact factor: 13.807

3.  Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.

Authors:  Li Wang; Ling Li; Hailong Zhang; Xiao Luo; Jingquan Dai; Shaolian Zhou; Justin Gu; Jidong Zhu; Peter Atadja; Chris Lu; En Li; Kehao Zhao
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

Review 4.  On mammary gland growth factors: roles in normal development and in cancer.

Authors:  Mien-Chie Hung
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

5.  Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.

Authors:  Weiqi Fu; Nan Liu; Qi Qiao; Mingzhu Wang; Jinrong Min; Bing Zhu; Rui-Ming Xu; Na Yang
Journal:  J Biol Chem       Date:  2016-02-29       Impact factor: 5.157

6.  Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase.

Authors:  Pawel K Mazur; Or Gozani; Julien Sage; Nicolas Reynoird
Journal:  Transl Cancer Res       Date:  2016-06       Impact factor: 1.241

Review 7.  Nonhistone Lysine Methylation in the Regulation of Cancer Pathways.

Authors:  Scott M Carlson; Or Gozani
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

Review 8.  Protein methylation at the surface and buried deep: thinking outside the histone box.

Authors:  Steven G Clarke
Journal:  Trends Biochem Sci       Date:  2013-03-13       Impact factor: 13.807

9.  Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.

Authors:  Shinya Hayami; Masanori Yoshimatsu; Abhimanyu Veerakumarasivam; Motoko Unoki; Yukiko Iwai; Tatsuhiko Tsunoda; Helen I Field; John D Kelly; David E Neal; Hiroki Yamaue; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Mol Cancer       Date:  2010-03-13       Impact factor: 27.401

10.  Histone methylation by NUE, a novel nuclear effector of the intracellular pathogen Chlamydia trachomatis.

Authors:  Meghan E Pennini; Stéphanie Perrinet; Alice Dautry-Varsat; Agathe Subtil
Journal:  PLoS Pathog       Date:  2010-07-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.